ArticlePharmaceuticals (Basel, Switzerland)2020
Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview.
Article in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 15 citations in OpenAlex.
- Pharmacokinetics and Renal Safety Evaluation of Colistin Methanesulfonate Sodium in Korean Healthy Male Volunteers: An Open-Label, Multiple-Dose Study.Drug design, development and therapy · 2026Trial
- Therapeutic Drug Monitoring of Amikacin and Colistin in Patients with Multidrug-Resistant Gram-Negative Infections Using a Portable Plasmonic Biosensor.Analytical chemistry · 2025Article
- Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy.Pharmaceutics · 2023Article
- Pharmacokinetics and pharmacodynamics of peptide antibiotics.Advanced drug delivery reviews · 2022Review
- Dose Optimization of Colistin: A Systematic Review.Antibiotics (Basel, Switzerland) · 2021Review
- Intravenous colistin in the treatment of multidrug-resistant gram-negative organism in tertiary hospital, Jazan, KSA.Journal of family medicine and primary care · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Colistin is used as a last-line antibiotic for the treatment of Gram-negative multiresistant bacteria. Due to its high nephrotoxicity, Therapeutic Drug Monitoring (TDM) is recommended for dose adjustment. We aimed to evaluate the available evidence of TDM in patients given colistin to treat Gram-negative infections. In this paper, we offer an overview, using an electronic search of the literature (published up to June 2019, without language restrictions) that compares the clinical outcomes and measurements of colistin TDM. Ultimately, the Therapeutic Drug Monitoring (TDM) of colistin in Plasma could prevent nephrotoxicity risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.